OVERVIEW

Expert Illustrations and Commentaries Live: The Future of JAK/TYK2 Inhibition in the Treatment of Psoriasis is organized by Physicians' Education Resource, LLC (PER).

Release Date: February 11, 2022
Expiration Date: February 11, 2023

Activity Overview:
This online, on-demand virtual symposium brings together renowned experts in dermatology to discuss newer treatments for patients with psoriasis. Psoriasis has no clearly defined cause or cure, but it does have a significant impact on quality of life. It is now recognized as a systemic disease associated with psoriatic arthritis and other serious comorbidities. The critical pathogenic pathway in psoriasis is considered to be the interleukin (IL)-23/IL-17 axis. This pathway uses the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway to transduce intracellular signals. Although small molecules that block the JAK/STAT pathway and reduce inflammation have been developed, their relative nonspecific nature and toxicity have hindered their use in patients with psoriasis. Current research is focused on tyrosine kinase 2 (TYK2) inhibitors, which have more favorable efficacy and safety profiles.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Describe the etiology, pathophysiology, and important considerations in the diagnosis of psoriasis.
• Evaluate the latest data on the efficacy, safety, dosing, and administration of novel TYK2 inhibitors for patients with psoriasis.
• Integrate targeted TYK2 inhibitors into the treatment of psoriasis.

Additional details will be posted as soon as information is available.